<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545788</url>
  </required_header>
  <id_info>
    <org_study_id>GCP-TB</org_study_id>
    <nct_id>NCT04545788</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis</brief_title>
  <official_title>A Randomized, Controlled, Multi-center Clinical Trial of Short Course Treatment for Newly Diagnosed Rifampicin Resistant Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, controlled, multi-center clinical study. The main purpose of this&#xD;
      study was to study the efficacy and safety data of total oral short-term therapy as an&#xD;
      alternative to injection in the treatment of newly diagnosed RR-TB patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A group: 4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx B group: 4-6 INH EMB PZA Pto LZD&#xD;
      Cfz Mfx / 5 EMB PZA Cfz Mfx C group: 4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (INH: Isoniazid,&#xD;
      EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx:&#xD;
      Moxifloxacin, LZD: Linezolid, BDQ: Bedaquiline, CS: Cycloserine) A group is the control group&#xD;
      which includes injectable drugs (AM). B group and C group are the experimental groups which&#xD;
      are total oral short-term therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Culture of Mycobacterium tuberculosis in sputum.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>Mycobacterium tuberculosis culture of sputum will be carried out every month to understand the negative conversion rate and time of sputum bacteria, and then to understand the cure rate of patients. The final aim is to understand the efficacy of the total oral short-term anti-tuberculosis regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effect.</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>All the types and frequency of adverse reactions that related to anti-tuberculosis drug were collected.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-6 INH EMB PZA Pto AM Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, AM: Amikacin, Cfz: Clofazimine, Mfx: Moxifloxacin) A group is the control group which includes injectable drugs (AM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-6 INH EMB PZA Pto LZD Cfz Mfx / 5 EMB PZA Cfz Mfx (INH: Isoniazid, EMB: Ethambutol, PZA: Pyrazinamide, Pto: Prothionamide, LZD: Linezolid, Cfz: Clofazimine, Mfx: Moxifloxacin) B group is the experimental groups which is total oral short-term therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-6 BDQ LZD MFX CS CFZ / 5MFX CS CFZ (BDQ: Bedaquiline, LZD: Linezolid, Mfx: Moxifloxacin, CS: Cycloserine, Cfz: Clofazimine) C group is another experimental groups which is also total oral short-term therapy, and includes new anti-TB drugs: BDQ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.</intervention_name>
    <description>AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent and accepted follow-up;&#xD;
&#xD;
          -  the age is between 18 and 65 years old, both male and female, including inpatients and&#xD;
             outpatients;&#xD;
&#xD;
          -  no use of anti tuberculosis drugs, or use of anti tuberculosis drugs less than 1&#xD;
             month;&#xD;
&#xD;
          -  the results of molecular biology test confirmed rifampicin resistance or MDR-TB&#xD;
             patients;&#xD;
&#xD;
          -  chest CT examination confirmed pulmonary tuberculosis, pulmonary lesions, or cavity;&#xD;
&#xD;
          -  premenopausal women had negative pregnancy urine test and agreed to use&#xD;
             high-efficiency contraceptive measures during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  drug sensitivity test or molecular drug sensitivity results show that the drug&#xD;
             resistance (except isoniazid) or any component of the drug has a history of allergy,&#xD;
             or is taking any drug that is contraindicated to the drug in the short-term treatment&#xD;
             program;&#xD;
&#xD;
          -  severe renal insufficiency (creatinine clearance rate (CrCl) less than 30 ml / min).&#xD;
&#xD;
          -  liver function impairment (ALT and / or AST level 3 times higher than the upper limit&#xD;
             of laboratory reference value, if it is temporary increase, it can be included after&#xD;
             treatment recovery);&#xD;
&#xD;
          -  those who are unable to participate in or comply with the treatment and follow-up;&#xD;
&#xD;
          -  Q-T interval &gt; 450 millisecond;&#xD;
&#xD;
          -  have a history of cardiovascular diseases or are suffering from such diseases as heart&#xD;
             failure, hypertension (poor blood pressure control), arrhythmia or post myocardial&#xD;
             infarction state;&#xD;
&#xD;
          -  pregnant or lactating women;&#xD;
&#xD;
          -  those who are unable to take oral drugs;&#xD;
&#xD;
          -  those who are currently participating in other clinical trials;&#xD;
&#xD;
          -  patients with HIV positive or active viral hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NAIHUI CHU, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chest Hospital affiliated to Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WENJUAN NIE, Director</last_name>
    <phone>+86 13552156672</phone>
    <email>wenjuan.nie@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JING LIU, Doctor</last_name>
    <phone>+86 13810654836</phone>
    <email>liujingworkbj@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chest Hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NAIHUI CHU, Director</last_name>
      <phone>+86 10 89509301</phone>
      <email>dongchu1994@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H, Chen W, Liu Y, Li C, Xi X, Yin H, Zeng J, Zhang X, Xu T, Wang Q, Guo R, Wang J, Pang Y, Chu N. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clin Infect Dis. 2020 Aug 14;71(4):1047-1054. doi: 10.1093/cid/ciz915.</citation>
    <PMID>31549147</PMID>
  </reference>
  <reference>
    <citation>Wang Q, Pang Y, Jing W, Liu Y, Wang N, Yin H, Zhang Q, Ye Z, Zhu M, Li F, Liu P, Wu T, Chen W, Wu W, Qin Z, Qiu C, Deng Q, Xu T, Wang J, Guo R, Du Y, Wang J, Huang H, Chen X, Chu N. Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China. Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02149-17. doi: 10.1128/AAC.02149-17. Print 2018 Apr.</citation>
    <PMID>29378718</PMID>
  </reference>
  <reference>
    <citation>Wang J, Pang Y, Jing W, Chen W, Guo R, Han X, Wu L, Yang G, Yang K, Chen C, Jiang L, Cai C, Dou Z, Diao L, Pan H, Wang J, Du F, Xu T, Wang L, Li R, Chu N. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist. 2019 Apr 3;12:763-770. doi: 10.2147/IDR.S194484. eCollection 2019.</citation>
    <PMID>31040707</PMID>
  </reference>
  <reference>
    <citation>Pang Y, Jing W, Lu J, Zong Z, Huo F, Dong L, Dai G, Li Y, Huang H, Chu N. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Diagn Microbiol Infect Dis. 2019 Aug;94(4):361-364. doi: 10.1016/j.diagmicrobio.2019.02.012. Epub 2019 Feb 19.</citation>
    <PMID>30876684</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chest Hospital</investigator_affiliation>
    <investigator_full_name>Chu naihu</investigator_full_name>
    <investigator_title>TB Director</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis, rifampin resistant, oral, shorter.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

